Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population-based case-control study
Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population-based case-control study
BACKGROUND: Patients using higher dosages of inhaled or oral glucocorticoids (GCs) have an increased risk of hip/femur fractures. The role of the underlying disease in the aetiology of this increased risk has not been widely studied. OBJECTIVE: To evaluate the contribution of the underlying disease to the risk of hip/femur fracture in patients using inhaled or oral GCs. DESIGN AND SUBJECTS: A case-control study within the Dutch PHARMO-RLS database was conducted. Cases (n = 6763) were adult patients with a first hip/femur fracture during enrolment. Each case was matched to four controls by age, gender and region. RESULTS: The risk of hip/femur fracture increased with current use of inhaled GCs (crude OR 1.30, 95% CI:1.16-1.47) and with current use of oral GCs (crude OR 1.66, 95% CI: 1.46-1.90). After adjustment for disease severity, the risk of hip/femur fracture was no longer statistically significantly increased in inhaled GC users (adjusted OR 1.08, 95% CI: 0.91-1.27), whilst it remained elevated in oral GC users (adjusted OR 1.43, 95% CI: 1.22-1.67). Patients using inhaled GCs without any exposure to oral GCs had no increased risk of fracture (adjusted OR 0.98, 95% CI: 0.79-1.22). CONCLUSION: Inhaled GC users had no increased risk of femur/hip fracture after adjustment for underlying disease severity. Our data suggest that, even at higher dosages, inhaled GC use is not an independent risk factor for fracture. In contrast, oral GC use was associated with an increased risk of fracture, which was not fully explained by the underlying disease severity.
lung diseases, obstructive, confounding factors (epidemiology), glucocorticoids, hip fractures
170-177
de Vries, F.
db4c0543-d6e7-476b-a10e-52d9d483f613
Pouwels, S.
3d97460d-5b2e-4ec6-b46f-e82e338cf0c1
Lammers, J.W.J.
5ac44075-3876-4448-a783-65b0a2d2633f
Leufkens, H.M.G.
37d702d1-bd5e-4477-9b5f-1ba96d4c5a7c
Bracke, M.
24331ee3-1101-44d0-9606-01d12c011f8f
Cooper, C.
e05f5612-b493-4273-9b71-9e0ce32bdad6
Van Staa, T.P.
31b8bfb4-4e1b-4a48-a5a6-90ca601b94af
February 2007
de Vries, F.
db4c0543-d6e7-476b-a10e-52d9d483f613
Pouwels, S.
3d97460d-5b2e-4ec6-b46f-e82e338cf0c1
Lammers, J.W.J.
5ac44075-3876-4448-a783-65b0a2d2633f
Leufkens, H.M.G.
37d702d1-bd5e-4477-9b5f-1ba96d4c5a7c
Bracke, M.
24331ee3-1101-44d0-9606-01d12c011f8f
Cooper, C.
e05f5612-b493-4273-9b71-9e0ce32bdad6
Van Staa, T.P.
31b8bfb4-4e1b-4a48-a5a6-90ca601b94af
de Vries, F., Pouwels, S., Lammers, J.W.J., Leufkens, H.M.G., Bracke, M., Cooper, C. and Van Staa, T.P.
(2007)
Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population-based case-control study.
Journal of Internal Medicine, 261 (2), .
(doi:10.1111/j.1365-2796.2006.01754.x).
Abstract
BACKGROUND: Patients using higher dosages of inhaled or oral glucocorticoids (GCs) have an increased risk of hip/femur fractures. The role of the underlying disease in the aetiology of this increased risk has not been widely studied. OBJECTIVE: To evaluate the contribution of the underlying disease to the risk of hip/femur fracture in patients using inhaled or oral GCs. DESIGN AND SUBJECTS: A case-control study within the Dutch PHARMO-RLS database was conducted. Cases (n = 6763) were adult patients with a first hip/femur fracture during enrolment. Each case was matched to four controls by age, gender and region. RESULTS: The risk of hip/femur fracture increased with current use of inhaled GCs (crude OR 1.30, 95% CI:1.16-1.47) and with current use of oral GCs (crude OR 1.66, 95% CI: 1.46-1.90). After adjustment for disease severity, the risk of hip/femur fracture was no longer statistically significantly increased in inhaled GC users (adjusted OR 1.08, 95% CI: 0.91-1.27), whilst it remained elevated in oral GC users (adjusted OR 1.43, 95% CI: 1.22-1.67). Patients using inhaled GCs without any exposure to oral GCs had no increased risk of fracture (adjusted OR 0.98, 95% CI: 0.79-1.22). CONCLUSION: Inhaled GC users had no increased risk of femur/hip fracture after adjustment for underlying disease severity. Our data suggest that, even at higher dosages, inhaled GC use is not an independent risk factor for fracture. In contrast, oral GC use was associated with an increased risk of fracture, which was not fully explained by the underlying disease severity.
This record has no associated files available for download.
More information
Published date: February 2007
Keywords:
lung diseases, obstructive, confounding factors (epidemiology), glucocorticoids, hip fractures
Identifiers
Local EPrints ID: 61056
URI: http://eprints.soton.ac.uk/id/eprint/61056
ISSN: 0954-6820
PURE UUID: dff47e2c-7378-4a36-8b6b-432135f78152
Catalogue record
Date deposited: 25 Sep 2008
Last modified: 18 Mar 2024 02:44
Export record
Altmetrics
Contributors
Author:
F. de Vries
Author:
S. Pouwels
Author:
J.W.J. Lammers
Author:
H.M.G. Leufkens
Author:
M. Bracke
Author:
T.P. Van Staa
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics